Will Insider Stock Sales Amid EXPAND Xenotransplantation Progress Change United Therapeutics' (UTHR) Narrative?

Simply Wall St.12-18

In December 2025, several United Therapeutics insiders, including officer Paul A. Mahon and directors Jan Malcolm and Christopher Patusky, disclosed past sales of company stock totaling more than US$...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2592218904?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2025-12-18 21:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2592218904","market":"hk","top_or_hot":-1,"title":"Will Insider Stock Sales Amid EXPAND Xenotransplantation Progress Change United Therapeutics' (UTHR) Narrative?","media":"Simply Wall St.","content":"<div>\n<p>In December 2025, several United Therapeutics insiders, including officer Paul A. Mahon and directors Jan Malcolm and Christopher Patusky, disclosed past sales of company stock totaling more than US$...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-uthr/united-therapeutics/news/will-insider-stock-sales-amid-expand-xenotransplantation-pro\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Will Insider Stock Sales Amid EXPAND Xenotransplantation Progress Change United Therapeutics' (UTHR) Narrative?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWill Insider Stock Sales Amid EXPAND Xenotransplantation Progress Change United Therapeutics' (UTHR) Narrative?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-18 21:16 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-uthr/united-therapeutics/news/will-insider-stock-sales-amid-expand-xenotransplantation-pro><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In December 2025, several United Therapeutics insiders, including officer Paul A. Mahon and directors Jan Malcolm and Christopher Patusky, disclosed past sales of company stock totaling more than US$...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-uthr/united-therapeutics/news/will-insider-stock-sales-amid-expand-xenotransplantation-pro\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PRGS","symbol_name":"Progress Software Corporation","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-uthr/united-therapeutics/news/will-insider-stock-sales-amid-expand-xenotransplantation-pro","article_id":"2592218904","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-uthr/united-therapeutics/news/will-insider-stock-sales-amid-expand-xenotransplantation-pro","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2592218904","pubTimestamp":1766063767,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"In December 2025, several United Therapeutics insiders, including officer Paul A. Mahon and directors Jan Malcolm and Christopher Patusky, disclosed past sales of company stock totaling more than US$5.33 million, as required under federal securities laws.\nThese insider transactions came as analysts highlighted encouraging clinical progress, including the first clinical xenotransplantation in the EXPAND study, alongside a solid operational backdrop for United Therapeutics.\nWe’ll explore how...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"PRGS":"Progress Software Corporation","UTHR":"美国联合医疗"},"translate_title":"随着异种移植进展的扩大，内幕股票销售会改变联合治疗公司(UTHR)的叙述吗？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PRGS":1.5,"UTHR":1.5},"content_text":"In December 2025, several United Therapeutics insiders, including officer Paul A. Mahon and directors Jan Malcolm and Christopher Patusky, disclosed past sales of company stock totaling more than US$5.33 million, as required under federal securities laws. These insider transactions came as analysts highlighted encouraging clinical progress, including the first clinical xenotransplantation in the EXPAND study, alongside a solid operational backdrop for United Therapeutics. We’ll explore how positive sentiment around the EXPAND xenotransplantation milestone and broader clinical momentum may influence United Therapeutics’ investment narrative. Explore 28 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.United Therapeutics Investment Narrative RecapTo own United Therapeutics, you need to believe its pulmonary franchise can keep funding a high-cost push into organ manufacturing and xenotransplantation. The recent insider sales, totaling over US$5.33 million, do not appear to alter the key near term catalyst around Tyvaso’s TETON IPF program or the main risk that heavy R&D on ambitious projects like EXPAND may not translate into commercially viable products on the expected timelines. The EXPAND UKidney xenotransplantation milestone is the clearest link between the insider activity and the current investment story, since analysts have cited it when raising price targets. As this program moves forward, its progress will likely sit alongside TETON IPF data as one of the main clinical signposts investors watch to gauge how much the innovation wave might offset intensifying competition in pulmonary arterial hypertension. Yet investors should also keep in mind how dependent United Therapeutics still is on a concentrated pulmonary portfolio and what that means if treatment paradigms shift toward... Read the full narrative on United Therapeutics (it's free!)United Therapeutics' narrative projects $3.7 billion revenue and $1.5 billion earnings by 2028.Uncover how United Therapeutics' forecasts yield a $518.25 fair value, in line with its current price.Exploring Other PerspectivesUTHR 1-Year Stock Price Chart Five fair value estimates from the Simply Wall St Community span roughly US$280 to over US$1,346, reflecting sharply different expectations. You can weigh those views against the central catalyst around Tyvaso’s potential IPF expansion and consider how a setback there could reshape the company’s longer term earnings profile.Explore 5 other fair value estimates on United Therapeutics - why the stock might be worth 45% less than the current price!Build Your Own United Therapeutics NarrativeDisagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.A great starting point for your United Therapeutics research is our analysis highlighting 4 key rewards that could impact your investment decision.Our free United Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate United Therapeutics' overall financial health at a glance.Contemplating Other Strategies?Our daily scans reveal stocks with breakout potential. Don't miss this chance:The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.Outshine the giants: these 26 early-stage AI stocks could fund your retirement.AI is about to change healthcare. These 29 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Mobile Infrastructure for Defense and DisasterThe next wave in robotics isn't humanoid. Its fully autonomous towers delivering 5G, ISR, and radar in under 30 minutes, anywhere.Get the investor briefing before the next round of contractsSponsored On Behalf of CiTechNew: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2592218904","isCrawlerRequest":true}